Prognostic Biomarkers for Hodgkin Lymphoma

Abstract

The prognosis of patients with classical Hodgkin lymphoma following chemo- and radiotherapy has been excellent during the last 4 decades. However, the development of secondary malignancies is of major concern. Therefore, the reduction of radiotherapy application is a major objective of ongoing clinical trials. De-escalation of treatment may increase the risk of relapses and thus may lead to reappearance of prognostic factors. Prognostic biomarkers might help to identify patients who are at increased risk of relapse. This review summarizes the current knowledge about potential prognostic biomarkers for patients with classical Hodgkin lymphoma.

Keywords :

• gene expression
• Hodgkin lymphoma
• prognostic factors
• therapy resistance

ACKNOWLEDGMENTS

We thank Ines Volkmer for excellent technical assistance.

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.